Company news
MBX Biosciences, Inc. news in 2025
MBX Biosciences, Inc.'s news releases, calls and decks from 2025, newest first.
MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
December 14, 2025
MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference
November 17, 2025
MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 5, 2025
MBX Biosciences to Participate in November Investor Conferences
October 19, 2025
MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum
September 28, 2025
MBX Biosciences Announces Pricing of Upsized Public Offering
September 23, 2025
MBX Biosciences Announces Proposed Public Offering
September 21, 2025
MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension
September 21, 2025
MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22
September 18, 2025
MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity
September 3, 2025
MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
August 6, 2025
MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development
June 22, 2025
MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity
June 15, 2025
MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions
June 9, 2025
MBX Biosciences to Participate in June Investor Conferences
May 19, 2025
MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
May 11, 2025
MBX Biosciences to Participate in Citizens and RBC May Investor Conferences
April 21, 2025
MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors
April 6, 2025
MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
March 25, 2025
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
March 16, 2025
MBX Biosciences Announces Additions to Leadership Team
March 4, 2025
MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism
March 2, 2025
MBX Biosciences to Participate in March Investor Conferences
February 17, 2025
MBX Biosciences to Participate in Upcoming February Investor Conferences
January 22, 2025
MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia
January 6, 2025
Calls in 2025
Decks in 2025
- Technical Presentation (September 2025)
Technical · 29 slides · Sep 22, 2025
- Investor Presentation (June 2025)
Investor deck · 37 slides · Jun 9, 2025